Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Artesunate - Frantz Viral Therapeutics

Next Previous
Drug Profile

Artesunate - Frantz Viral Therapeutics

Alternative Names: Artemisinin; Artesunic acid; Dihydroartemisinin

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgetown University
  • Developer Frantz Viral Therapeutics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class 3-ring heterocyclic compounds; Antimalarials; Artemisinins; Small molecules; Succinates
  • Mechanism of Action Cell inhibitors; Free radical stimulants; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anal intraepithelial neoplasia; Cervical intraepithelial neoplasia
  • No development reported Vulvar intraepithelial neoplasia

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Vulvar-intraepithelial-neoplasia(In the elderly, In adults) in USA (Topical, Ointment)
  • 09 Dec 2024 Frantz Viral Therapeutics completes a phase I trial in Vulvar intraepithelial neoplasia (In adults, In the elderly) in USA (Topical) (NCT03792516)
  • 15 Jan 2024 Frantz Viral Therapeutics plans a phase II trial for Anal High-grade Squamous Intraepithelial Lesion in USA (Rectal) (NCT06206564)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top